Trial of Dasatinib in Subjects With Advanced Cancers Harboring DDR2 Mutation or Inactivating B-RAF Mutation
by on Monday, January 23rd, 2012 | No Comments
Conditions: Carcinoma, Non-small Cell Lung; Melanoma
Intervention: Drug: Dasatinib
Sponsor: Bristol-Myers Squibb
Not yet recruiting – verified January 2012
See the rest here: Trial of Dasatinib in Subjects With Advanced Cancers Harboring DDR2 Mutation or Inactivating B-RAF Mutation